Critical Care

official impact factor 4.60

This article is part of the supplement: 24th International Symposium on Intensive Care and Emergency Medicine

Email this article to a friend

Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study

C Garratt, M Packer, W Colucci, L Fisher, B Massie, J Teerlink and J Young

Critical Care 2004, 8(Suppl 1):P89 doi:10.1186/cc2556

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.